1.Xiaopeng Peng, Wanyi Pan, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng, Jianjun Chen, Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy, Pharmacological Research 186 (2022)...
参考文献: [1]CT014.PETRA: first-in-human Phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BR...
参考文献: [1]CT014.PETRA: first-in-human Phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations.2024 AACR. 编辑:KI...
a next generation, highly selective PARP1 inhibitor and trapper.3
AZD5305 did not sensitize PDXs with acquired resistance to olaparib but elicited profound and durable responses when combined with carboplatin or ceralasertib in 3/6 and 5/5 models, respectively.Collectively, these results show that the novel PARP1 selective inhibitor AZD5305 yields a potent ...
近期,国际团队在Molecular Cancer Therapeutics(AACR)在线发表了题为"Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety"的文章,合成了新型强效PARP抑制剂维那达帕利(Venadaparib,也称为IDX-1197或NOV140101),评估了Venadaparib对PARP酶、PAR形成和PARP...
近期,国际团队在Molecular Cancer Therapeutics(AACR)在线发表了题为"Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety"的文章,合成了新型强效PARP抑制剂维那达帕利(Venadaparib,也称为IDX-1197或NOV140101),评估了Venadaparib对PARP酶、PAR形成和PARP...
近期,国际团队在Molecular Cancer Therapeutics(AACR)在线发表了题为"Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety"的文章,合成了新型强效PARP抑制剂维那达帕利(Venadaparib,也称为IDX-1197或NOV140101),评估了Venadaparib对PARP酶、PAR形成和PARP...
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305 improved selectivity for PARP1, expanding significant clinical values and wide application prospects both in monotherapy and combination with other anticancer ... J Zheng,Z Li,W Min - 《...
“Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.” Cancer cell vol. 33,6 (2018): 1078-1093.e12. doi:10.1016/j.ccell.2018.05.008 编辑于 2023-03-06 09:47・IP 属地上海 靶向药 癌症靶向治疗 癌症...